Navigation Links
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Date:11/21/2013

DUBLIN, Ireland, November 21, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/98bhmb/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed.

This report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Key Topics Covered:

1. Overview

2. Introduction

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes

4. Pharmaceutical Industry and the Anti-Diabetes Market

5. Non-Insulin Anti-Diabetes Products

6. Insulin

7. Emerging Anti-Diabetes Products

8. Diagnosing Diabetes Using In Vitro Laboratory Tests

9. Market Trends, Challenges and Strategic Options

10. Company Profiles

Companies Mentioned

- Menarini
- Abbott Laboratories
- Amgen
- AstraZeneca
- Bayer
- BodyMedia
- Cybermedical
- Debiotech
- DexCom
- Echo Therapeutics
- Elixir Pharmaceuticals
- Eksigent
- Flamel Technologies
- GlaxoSmithKline
- GlucoLight
- Insulet
- iSense Corporation
- Isis Pharmaceuticals, Inc.
- Johnson & Johnson
- KYORIN
- M-Biotech
- Medtronic
- Merck & Co.
- Merck KGaA
- MicroIslet
- Mitsubishi Tanabe Pharma Corporation
- Nipro Diabetes Systems
- Novartis
- Novo Nordisk
- Novocell
- ONO Pharmaceutical
- Orexigen Therapeutics
- Pfizer
- ReNeuron
- Roche Diagnostics
- Sanofi-Aventis
- Siemens
- Smiths Medical
- Servier
- SOOIL Development
- Takeda
- TheraFuse
- Teco Diagnostics
- Transition Therapeutics
- U.S. Diagnostics
- VeraLight
- Vivus
- Ypsomed Holding

For more information visit http://www.researchandmarkets.com/research/98bhmb/diabetes

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. La célebre chef Leticia Moreinos Schwartz se asocia con Merck en el marco del programa Cuida tu Diabetes, Cuida tu Corazón para preparar deliciosos platos para diabéticos destinados a los hispanos que padecen diabetes tipo 2
2. Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Cuida tu Diabetes, Cuida tu Corazon to Cook up Delicious, Diabetes-Friendly Dishes for Hispanics with Type 2 Diabetes
3. Neue klinische Richtlinien für ältere Patienten mit Typ 2 Diabetes, um einen europaweiten Pflegenotstand zu verhindern
4. Whats Next In Vaccines (Malaria, Diabetes, Alzheimers, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)
5. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
6. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
7. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
8. Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
9. Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
10. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
11. Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):